The population of China is not particularly obese relative to European or North American standards, but it is certainly getting heavier in parallel with the rapid expansion of the "Western diet and lifestyle". Now, 46% of adults in China are overweight or obese. More concerning, however, is the fact that Asian populations tend to develop cardiometabolic complications of overweight and obesity at a lower body mass index than Caucasians. As such, an estimated 110 million people in China are affected by type 2 diabetes mellitus, and 50% of the population has cardiovascular disease. The mechanisms underlying this higher susceptibility remain unclear, so investigating this problem is important as it could have a major impact on public health in China.
Our research programme in Nanjing will focus on elucidating the mechanisms that link obesity to its associated cardiometabolic complications, with a particular focus on genetic factors identified in human populations. The laboratory in Cambridge has proposed two key conceptual paradigms: the adipose tissue expandability model and the concept of lipotoxicity. We have shown that the metabolic comorbidities of obesity typically occur when adipose tissue expansion fails and lipids cannot be stored efficiently. Thus, excess lipids that cannot be stored "spill over" to peripheral organs where the accumulation of lipids causes lipotoxicity. If genetic factors were to limit the expansion capacity of adipose tissue, this process may happen at an earlier stage in weight gain, resulting in the metabolic complications of obesity appearing earlier than expected. This research is relevant for the global obesity epidemic, but may be even more relevant for the obese population in China. Research on these mechanisms in Nanjing will be highly integrated with the research programme in Cambridge, and will benefit from access to the international network of experts collaborating with our laboratory.
Currently, our collaboration with Nanjing is proving more useful than ever, with their great and continued support in the 4CPPE Appeal - read more here. To find out more about this research and the Centre as a whole, visit our website, the Centre's Twitter page, or watch this interview with Prof Vidal-Puig.
TVPLab in Nanjing
The Cambridge University - Nanjing Centre of Technology and Innovation, in Nanjing, China, is the first research institution established by the University of Cambridge outside of the United Kingdom. The Centre will seek to demonstrate the power of collaboration with China’s Universities, industry, government and other partners to conduct the kind of academic research of excellence today that will make life better for the city dwellers of tomorrow. Ground was broken at the site of the new Centre in September 2019, with research due to commence there this year, including research on the cardiometabolic complications of obesity in Asian populations by the TVPLab.
TVPLab in Cambridge University Nanjing Centre of Technology and Innovation
We are contribute to educate the lay public from China about obesity and associated complications, which are a major problem in China. To read whole interview with
Prof. Antonio Vidal-Puig click on the link bellow:
news details (cunjc.org.cn)
Professor Antonio Vidal-Puig, member of the Academic Committee of Enlian Research Institute, academician of the British Academy of Medical Sciences, and Cambridge University, came to Guangdong, Hong Kong and Macao Biotechnology to carry out academic exchanges!
Dongguan Regional Cell Preparation Center 2022-11-17 12:19 Posted on Guangdong
On November 16, 2022 , Professor Antonio Vidal-Puig, a member of the Academic Committee of Enlian Stem Cell Biotechnology Research Institute , a member of the British Academy of Medical Sciences, and the University of Cambridge, visited Dongguan Guangdong-Hong Kong-Macau Stem Cell Biotechnology Co., Ltd. and Enlian Research Institute to conduct in-depth discussions. Academic exchange. Wu Pingping, chairman of Guangdong-Hong Kong-Macau Biotechnology, and Tan Fengming, general manager, warmly welcomed and accompanied the visit and discussion.
Professor Antonio Vidal-Puig received his Doctor of Medicine degree from Valencia University School of Medicine in Spain in 1986, and his Doctor of Philosophy degree from Granada University School of Medicine in 1992. He has engaged in research work at Harvard Medical School and Cambridge University, and is currently at Cambridge University . Professor of Molecular Nutrition and Metabolic Biology, mainly engaged in research on the molecular mechanism of obesity and insulin resistance, the molecular mechanism of diabetes and cardiometabolic abnormal complications, and related drug intervention strategies. Published more than 170 papers in multiple international authoritative journals such as Nature, Cell, etc. He serves as the editorial board member of many international authoritative journals such as Diabetes and Biochemical Journal.
Professor Antonio Vidal-Puig walked into the GMP laboratory of the Enlian Research Institute to learn more about the stem cell laboratory and its functional divisions, advanced equipment, experimental platforms, and cooperation progress . The system standards are fully affirmed, and some forward-looking opinions with practical value and significance are put forward. It is hoped that our company will truly break through scientific research bottlenecks and technical barriers by strengthening close cooperation with scientific research institutions , continuously carry out product research and development updates, and accelerate the transformation of research results. .
Subsequently, Prof. Antonio Vidal-Puig, general manager of Guangdong-Hong Kong-Macao Biotechnology Tan Fengming, Dean of Enlian Research Institute Dr. Zou Jiangying, and the academic committee team of the research institute conducted in-depth discussions on the future development of the research institute, stem cell basic and clinical research , etc. through video conferences . Academic discussions and exchanges provide technical guidance and inspiration to the academic committee team of the institute. I believe that the new ideas, new methods, and new insights brought about by the close exchanges between the two sides in the future will have important guiding and practical significance for the academic vision of our company and the team members of the research institute, and for the inspiration of academic research ideas.
We are deeply honored and benefited a lot from the visiting guidance of Professor Antonio Vidal-Puig. Stem cells are the frontier field of the biomedicine and health industry. It is believed that in the future, Guangdong, Hong Kong and Macao biotechnology will closely follow the pace of national scientific research development and international frontiers, actively build a "bridge" between scientific research and industry, continue to improve clinical research and transformation capabilities, and provide cells Provide strong support for the development of the field of treatment and drug research and development, empowering and adding value to the development of human health.
"I like the vitality of Nanjing!" Interview with Professor Antonio Vidal-Puig from Cambridge University
Cambridge University Nanjing Science and Technology Innovation Center
From a clinician to a university professor, from Spain to the United States to Cambridge, England, Professor Antonio Vidal-Puig has been committed to exploring the relationship between obesity, metabolic diseases and genes, so as to help obese people better cope with complications.
As the PI of the center's "Research on the Mechanism and Control Strategies of Obesity-Related Metabolic Complications", in the previous PI online interview , Antonio Vidal-Puig, Professor of Molecular Nutrition and Metabolism at the University of Cambridge, shared the research principles and application prospects of the project During his short-term exchange in China recently, he talked face-to-face with his rich research experience, global academic outlook, and good impression of Nanjing. Let us enter the world of Professor Vidal-Puig through the interview.